Oishi Masayo, Hiro Shintaro, Matsuoka Nobushige, Hotta Shinichi, Ono Ryosuke, Mori Yuko, Takenaka Nobuko, Uchikawa Yoko, Arakawa Akio, Yuasa Hirotoshi, Ishibashi Taro, Miyoshi So, Hirai Kanji, Kawai Norisuke
1 Pfizer Japan Inc, Tokyo, Japan Presented at the Drug Information Association's 48th annual meeting; June 28, 2012; Philadelphia, Pennsylvania, USA.
Ther Innov Regul Sci. 2014 May;48(3):393-403. doi: 10.1177/2168479013517892.
Global clinical studies conducted in various countries and regions are increasing. Race and extrinsic ethnic factors are key covariates that may affect the pharmacokinetics (PK), efficacy, and safety of the drug. Genetic similarity among East Asian populations has been confirmed; thus, PK, efficacy, and safety in these populations are expected to be similar, but this has not been confirmed. This study presents a comparison of PK and safety among East Asians from clinical studies sponsored by Pfizer. Four compounds with different characteristics, including mechanism of actions and PK profiles, were selected, and retrospective PK and safety comparisons in East Asians were conducted. No distinct differences were observed in PK and safety across the 4 compounds. These results are consistent with previous reports on PK comparisons and meet the expectations based on genetic similarity among East Asians. Extrapolation of these findings to other compounds should be done with caution, but these results should support the consideration of mutual use of clinical data among East Asian countries.
在各个国家和地区开展的全球临床研究正在增加。种族和外在的种族因素是可能影响药物药代动力学(PK)、疗效和安全性的关键协变量。东亚人群之间的基因相似性已得到证实;因此,预计这些人群中的PK、疗效和安全性会相似,但这尚未得到证实。本研究对辉瑞赞助的临床研究中的东亚人群的PK和安全性进行了比较。选择了四种具有不同特性(包括作用机制和PK概况)的化合物,并对东亚人群进行了回顾性PK和安全性比较。在这4种化合物的PK和安全性方面未观察到明显差异。这些结果与先前关于PK比较的报告一致,并符合基于东亚人群基因相似性的预期。将这些发现外推至其他化合物时应谨慎,但这些结果应支持考虑东亚国家之间临床数据的相互使用。